1.
Bioorg Med Chem Lett
; 22(21): 6688-93, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23031591
RESUMO
A series of dual CCR3/H(1) antagonists based on a bispiperidine scaffold were discovered. Introduction of an acidic group overcame hERG liability. Bioavailability was optimised by modulation of physico-chemical properties and physical form to deliver a compound suitable for clinical evaluation.